CT

Kohl’s Season of Savings Continues with Black Friday Early Access Event and Unveiling of Black Friday Week Deals

Retrieved on: 
星期五, 十一月 3, 2023
Family, Toys, Defense, Consumer Electronics, Technology, Consumer, Other Retail, Teens, Children, Baby, Maternity, Fashion, Cosmetics, Retail, Online Retail, Jewelry, Other Consumer, Discount, Variety, Home Goods, Department Stores, Women, Men, Veterans, Card, NYSE, Military personnel, Fenty, Kohl's, Adidas, Collection, Sephora, Veteran, Nike, Life, Black Friday, LEGO, YAY, Ninja, Beautiful Inside My Head Forever, NO, CT, Amazon, KSS, Fireworks, Online shopping, Bookkeeping, Fashion design, Life insurance, Human back, Sweepstake

Kohl’s (NYSE: KSS) announced today the kick off to a November packed with its annual Black Friday Early Access event and the unveiling of the retailer’s plans for Black Friday Week – including the first look at its Black Friday ad .

Key Points: 
  • Kohl’s (NYSE: KSS) announced today the kick off to a November packed with its annual Black Friday Early Access event and the unveiling of the retailer’s plans for Black Friday Week – including the first look at its Black Friday ad .
  • Black Friday Early Access Event - Nov. 3 - Nov. 9
    Beginning today, Friday, Nov. 3, through Thursday, Nov. 9, Kohl’s is giving customers plenty of ways to save on key gifts during its Black Friday Early Access event.
  • Shopping in stores on Black Friday is even more fun with the return of the YAY for Black Friday!
  • Words such as “believes,” “anticipates,” “plans,” “may,” “intends,” “will,” “should,” “expects" and similar expressions are intended to identify forward-looking statements.

New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
星期五, 十一月 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Regulatory T cell, Neoplasm, Lymphocytopenia, Society for Immunotherapy of Cancer, NSCLC, Renal cell carcinoma, Therapy, Eosinophil, Kidney, Cell, RCC, Abstract (summary), CD8, Artificial intelligence, SITC, Immunotherapy, Clinical trial, NK, Immunoglobulin G, Annual general meeting, CT, Lung cancer, Melanoma, Safety, Patient, Interleukin, CD25, Karen Teff, Toxic epidermal necrolysis, Pharmaceutical industry, Vaccine

The data also demonstrate early evidence of anti-tumor activity in patients with several solid tumor cancer types.

Key Points: 
  • The data also demonstrate early evidence of anti-tumor activity in patients with several solid tumor cancer types.
  • “These encouraging new data support AU-007’s distinct advantages in the IL-2 class,” said Aron Knickerbocker, Aulos Bioscience’s chief executive officer .
  • At this point, we are observing the greatest anti-tumor activity in patients with tumors known to be sensitive to immune-modulating drugs.
  • These data support our decision to focus our Phase 2 expansion cohorts in melanoma, renal cell carcinoma and non-small cell lung cancer.

Observational Study Finds That Hyperfine, Inc. Portable MR Brain Imaging System Assists Clinicians in Early Detection of Acute Brain Injury in ECMO Patients

Retrieved on: 
星期四, 十一月 2, 2023
Health Technology, Health, Neurology, Medical Devices, Hyperfine structure, Stroke, FDA, MRI, Extracorporeal membrane oxygenation, Incidence, Brain damage, Mortality, ABI, Multimedia, CT, Brain, ECMO, Medical imaging, Patient, MD

The study evaluated the feasibility of using portable MR brain imaging for monitoring patients during ECMO use, highlighting its potential advantage in providing early visualization of ischemic stroke compared to computerized tomography (CT) scans.

Key Points: 
  • The study evaluated the feasibility of using portable MR brain imaging for monitoring patients during ECMO use, highlighting its potential advantage in providing early visualization of ischemic stroke compared to computerized tomography (CT) scans.
  • The initial findings of this study demonstrate the feasibility of using portable MR brain imaging with adult ECMO patients.
  • It concludes that the incidence of acute brain injury was high, with ischemic stroke being the most common type of injury.
  • “This may be particularly important when you consider mortality rates due to acute brain injury in ECMO patients and emphasizes the need for early and accurate neuromonitoring.”
    “The study’s findings are very encouraging, especially as they relate to the benefits of using the Swoop® portable brain imaging system for early assessment of acute brain injury in patients being treated with ECMO.

Mirion Launches Philanthropic Partnership with RAD-AID International

Retrieved on: 
星期三, 十一月 1, 2023
Research, Philanthropy, Training, Radiology, Health, Other Philanthropy, Other Science, Science, Education, DMC, NYSE, Therapy, MD, MIR, ATS, Partnership, Hospital, Radiation, CT, Developing country, Nuclear medicine, Medical imaging, Medical device

Mirion (NYSE: MIR), a leading provider of advanced radiation safety solutions, today announced a philanthropic partnership with RAD-AID International to help bring radiology and radiation safety education and capabilities to underserved populations around the world.

Key Points: 
  • Mirion (NYSE: MIR), a leading provider of advanced radiation safety solutions, today announced a philanthropic partnership with RAD-AID International to help bring radiology and radiation safety education and capabilities to underserved populations around the world.
  • As part of the partnership launch, Mirion made an in-kind donation to RAD-AID’s Medical Physics Program supporting healthcare efforts in Guyana, Grenada, Botswana, Morocco, Nigeria and Kenya.
  • By aligning with RAD-AID, Mirion aims to extend its impact beyond technological advancements and actively contribute to improving quality healthcare access and outcomes for vulnerable populations.
  • We look forward to leveraging our collective strengths across Mirion Technologies and Mirion Medical to support RAD-AID’s mission by empowering healthcare providers with the tools they need to save lives and improve patient outcomes.”

Newton Surgeon Using Groundbreaking Technology for Guided Personalized Shoulder Replacement Surgeries

Retrieved on: 
星期三, 十一月 1, 2023
Technology, Surgery, Medical Devices, Hospitals, Health Technology, Practice Management, Biotechnology, Hardware, Health, Anatomy, GPS, Surgeon, Shoulder, Scientific Reports, Glenoid fossa, CT, Patient, Dentistry, Satellite navigation device, Medical device, Arthroplasty

Orthopaedic surgeon Dr. Daniel Quinn is now using computer-assisted technology to offer guided personalized surgery for shoulder replacements in the area.

Key Points: 
  • Orthopaedic surgeon Dr. Daniel Quinn is now using computer-assisted technology to offer guided personalized surgery for shoulder replacements in the area.
  • ExactechGPS® Guided Personalized Surgery is the latest advancement in technology that provides surgeons with real-time visual guidance and alignment data in total shoulder surgery.
  • “With GPS, I have complete control over my patients’ shoulder replacement surgery,” said Dr. Quinn.
  • “This technology gives me the ability to pair each patient’s personalized plan prior to surgery with real-time intraoperative guidance to ensure proper implant placement.

The AZEK® Company Inc. Announces Fiscal Fourth Quarter and Full-Year 2023 Earnings Release and Investor Conference Call on November 28, 2023

Retrieved on: 
星期二, 十月 31, 2023
Architecture, Environment, Residential Building & Real Estate, Sustainability, Construction & Property, Landscape, NYSE, Performing arts of Australia, Maintenance, Chicago Tribune, Workplace, Real, ID, CT, Recycling, Wood, Clothing

That same day, the Company will hold a conference call to discuss the results at 4:00 p.m. (CT).

Key Points: 
  • That same day, the Company will hold a conference call to discuss the results at 4:00 p.m. (CT).
  • To access the live conference call, please register for the call in advance by visiting https://conferencingportals.com/event/BvLjpLVH .
  • After registering, a confirmation e-mail will be sent including dial-in details and unique conference call codes for entry.
  • Headquartered in Chicago, Illinois, the company operates manufacturing and recycling facilities in Ohio, Pennsylvania, Idaho, Georgia, Nevada, New Jersey, Michigan and Minnesota.

QuantalX Secures Dedicated Reimbursement Code for Delphi-MD Test, Advancing Improved Brain Health

Retrieved on: 
星期四, 十一月 2, 2023
Stroke, FDA, MRI, Medicare, Neurology, American Medical Association, Physician, Breakthrough, Doctor of Philosophy, Health, Dementia, AMA, DSM-IV codes, Caregiver, Myenteric plexus, NPH, Risk, CT, Brain, CPT, Patient, VPS, Pharmaceutical industry, Medical imaging

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- QuantalX Neuroscience, a pioneering healthcare company dedicated to early detection of brain disorders, is pleased to announce that it has secured a US reimbursement code, 0858T, from the American Medical Association (AMA). This milestone achievement is a significant part of the company's pre-commercialization strategy in the US.

Key Points: 
  • QuantalX announces the authorization of a dedicated US reimbursement code for its point-of-care brain health test by the American Medical Association (AMA).
  • NEW YORK, Nov. 2, 2023 /PRNewswire/ -- QuantalX Neuroscience , a pioneering healthcare company dedicated to early detection of brain disorders, is pleased to announce that it has secured a US reimbursement code, 0858T, from the American Medical Association (AMA).
  • The newly assigned CPT code signifies Delphi-MD's importance in early brain health assessment, catering to brain health evaluation procedures at any clinical setting using a collaborative care model.
  • The Delphi-MD technology is  a first-in-class automated, Direct Neuro-Physiological technology to detect and assess brain abnormalities, as well as predict treatment response.

CECO ENVIRONMENTAL ANNOUNCES INVESTOR CONFERENCE SCHEDULE FOR NOVEMBER 2023

Retrieved on: 
星期四, 十一月 2, 2023
Environment, CT, Medical imaging

DALLAS, Nov. 2, 2023 /PRNewswire/ -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced its investor conference schedule for November 2023:

Key Points: 
  • DALLAS, Nov. 2, 2023 /PRNewswire/ -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced its investor conference schedule for November 2023:
    Chicago - 1:45 pm CT presentation and conducting meetings throughout the day.
  • Dallas – 8:00 am CT presentation and conducting meetings throughout the day.
  • New York – Conducting meetings throughout the day.

Spinal Cord Injury Market Likely to Exhibit Substantial Growth by 2032, Assesses DelveInsight | Companies to Watch Out - NervGen Pharma, StemCyte, Mitsubishi Tanabe Pharma America, AbbVie

Retrieved on: 
星期三, 十一月 1, 2023
LAS, United Kingdom, Triage, MRI, X-ray, Spine, Bone, Literature, SCI, Unaware, Rehabilitation, Intubation, QOL, Disease, Neurogenic shock, Development, Quality of life, Growth, Transport, Phenylephrine, Norepinephrine, Tetraplegia, CT, Spinal cord, Accident, Thrombus, AbbVie, Regenerative medicine, Trauma, Patient, Diagnosis, Bradycardia, VA, Pharmaceutical industry, Medical device, Trapping, Medical imaging, Research

LAS VEGAS, Nov. 1, 2023 /PRNewswire/ -- DelveInsight's Spinal Cord Injury Market Insights report includes a comprehensive understanding of current treatment practices, spinal cord injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • Leading spinal cord injury companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others are developing novel spinal cord injury drugs that can be available in the spinal cord injury market in the coming years.
  • Spinal cord injury represents a significant medical condition that results in a wide range of functional, psychological, and socioeconomic challenges.
  • The spinal cord injury epidemiology section provides insights into the historical and current spinal cord injury patient pool and forecasted trends for individual seven major countries.
  • To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs
    Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
    MT-3921: Mitsubishi Tanabe Pharma America Inc.

Spinal Cord Injury Market Likely to Exhibit Substantial Growth by 2032, Assesses DelveInsight | Companies to Watch Out - NervGen Pharma, StemCyte, Mitsubishi Tanabe Pharma America, AbbVie

Retrieved on: 
星期三, 十一月 1, 2023
LAS, United Kingdom, Triage, MRI, X-ray, Spine, Bone, Literature, SCI, Unaware, Rehabilitation, Intubation, QOL, Disease, Neurogenic shock, Development, Quality of life, Growth, Transport, Phenylephrine, Norepinephrine, Tetraplegia, CT, Spinal cord, Accident, Thrombus, AbbVie, Regenerative medicine, Trauma, Patient, Diagnosis, Bradycardia, VA, Pharmaceutical industry, Medical device, Trapping, Medical imaging, Research

LAS VEGAS, Nov. 1, 2023 /PRNewswire/ -- DelveInsight's Spinal Cord Injury Market Insights report includes a comprehensive understanding of current treatment practices, spinal cord injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • Leading spinal cord injury companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others are developing novel spinal cord injury drugs that can be available in the spinal cord injury market in the coming years.
  • Spinal cord injury represents a significant medical condition that results in a wide range of functional, psychological, and socioeconomic challenges.
  • The spinal cord injury epidemiology section provides insights into the historical and current spinal cord injury patient pool and forecasted trends for individual seven major countries.
  • To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs
    Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
    MT-3921: Mitsubishi Tanabe Pharma America Inc.